The present invention relates to metered dose aerosol canister and in particular to a metered dose aerosol canister providing a variable valve for administration of desired amounts of drug depending upon need.
Diabetes is a disease affecting million of people in the United States and millions more world-wide. For diagnosed diabetics a common treatment is the use of insulin therapy. Generally, a diabetic patient self-administers insulin by injection. Diabetes is one of the few diseases where doctors routinely allow the patient to self titrate, that is, determine the exact amount of dosage to deliver to themselves at any give time. This variability of dose creates problems when attempting to deliver the dose through means other than the traditional injection.
In an effort to provide for a non-invasive means of administering insulin and other systemic drugs, and thereby eliminate the need for syringes, aerosolized formulations have been theorized.
Heretofore, the studies and experiments in the pulmonary delivery of insulin have suffered from poor reproducibility of the dose to be inhaled. Typically, the known inhaler devices use a non-metered canister which, when the valve is depressed, continues to deliver its dose until the valve is released. In order to achieve variable dosing, it is necessary for the device to have complex circuitry and relays for electrical control of the valve. While functional, these devices are not commercially viable due to the expensive and heavy batteries. In addition, the packaging of all of these items leads to a rather large and unwieldy inhaler.
Aside from diabetes and its treatment with insulin, a number of other diseases require the active participation and understanding of the patient to provide for effective dosing. For example, many people suffer from chronic obstructive pulmonary disease (COPD) and asthma.
Thus there is a need for a device and method providing for the effective and variable dosing for a patient to insure that effective amounts of drug are received at the desired time. There is a further need that such a device is user friendly providing adequate administration of the drug preferably in a single inhalation.
The present invention endeavors to overcome the problems of the prior art and provide a non-invasive device and methodology for delivery of drugs that produces repeatable and variable/controlled dosage amounts of a drug to the patient substantially without the need for complex circuitry having high energy demands.
One aspect of the instant invention is directed to a variable volume medicament valve including a housing; and a plug insertable into the housing wherein a volume of medicament to be released by the valve is defined by a distance between a lower surface of the plug and a top surface of the housing and wherein the volume is variable.
Another aspect of the present invention is a variable dose metered inhaler including an inhaler body, a canister for storage of one or more pressurized doses of a medicament which is placed in the inhaler body, and a dose variable valve, the dose variable valve including a valve housing and a valve plug, wherein a volume of drug to be administered can be varied by movement of the valve plug in relation to the valve housing.
A further aspect of the instant invention is a breath actuated variable dose metered inhaler including an inhaler body having a mouthpiece, a canister for storage of one or more pressurized doses of a medicament which is placed in the inhaler body, and a dose variable valve. The dose variable valve includes a valve housing and a valve plug, wherein a volume of drug to be administered can be varied by movement of the valve plug in relation to the valve housing. The breath actuated variable dose metered inhaler also includes a breath actuated trigger which releases the volume of drug to be administered to the mouthpiece upon inhalation by a user.
Yet a further aspect of the instant invention is a variable dose metered nasal drug delivery device including a nasal drug delivery device body having a mouthpiece and a nosepiece, a canister for storage of one or more pressurized doses of a medicament, and a dose variable valve. The dose variable valve includes a valve housing and a valve plug, wherein a volume of drug to be administered can be varied by movement of the valve plug in relation to the valve housing. The variable dose metered nasal drug delivery device also includes a breath actuated trigger which releases the volume of drug to be administered to the nosepiece upon the exhalation of a user into the mouthpiece.
An additional aspect of the instant invention is a method of treatment by application of a drug effective for the treatment including steps of providing a breath actuated inhaler, providing a pressurized container having a medication, and setting a dose based upon the need of the patient. The method also includes steps of inhaling on a mouthpiece of the breath actuated inhaler, and delivering the set dose to the patient.
Another aspect of the instant invention is a method of treatment of a condition in need thereof by application of a drug effective for the treatment thereof including steps of providing a breath actuated nasal drug deliver device, providing a pressurized container having a medication, and setting a dose dependent upon the instant need of the patient. The method also includes steps of exhaling in a mouthpiece of the breath actuated nose drug delivery device, and delivering the set dose to the patient via a nose piece.
A further aspect of the present invention is a method of varying the volume of a valve for release of a pressurized material including steps of providing a variable volume medicament valve having a housing, and a plug insertable into the housing wherein a volume of medicament to be released by the valve is defined by a distance between a lower surface of the plug and a top surface of the housing, and rotating the housing relative to the plug to change the distance.
Further characteristics, features, and advantages of the present invention will be apparent upon consideration of the following detailed description of the invention taken in conjunction with the following drawings, and in which:
A gathering ring 28 rests on top of the flange 20 of the metering chamber housing 18 and between the body 24 of the metering dosing chamber and the side wall 30 of the ferrule 12. When installed on a canister (not shown) by crimping, the gathering ring 28 is compressed and forms an air tight seal between the ferrule and the canister to prevent escape of the pressurized medicament and propellant.
The lower stem 32 of the dose variable valve 10 is inserted into lower stem seal 14 up to the hub 34. The lower stem 32 extends through the ferrule 12 and also into the metering chamber housing 18. The lower stem 32 includes an orifice 36 that, as will be described below, allows medicament to flow from the metering chamber through the lower stem and be dispensed to the patient. The lower stem 32 is hollow and has an opening on the distal end 38, proximal to the tab 40. A lumen connects the opening at the distal end 38 to the orifice 36. The tab 40, as will be discussed below provides a point that can be grasped or fit in a keyway allowing the application of pressure to rotate the valve stem 32 to change the volume of the metering chamber. The lower stem 32 also includes a slot 42 for engaging the upper stem.
A variable metering plug 44 can be inserted into the meter chamber housing 18. The variable metering plug 44 includes threads that correspond to the threads 26 formed on the inside of the metering chamber housing. A metering chamber seal 48 can be affixed to a lower portion of the variable metering plug 44 and prevents the drug or propellant from entering the metering chamber between the metering chamber plug 44 and the metering chamber housing 18. This in reality is only a problem during discharge of the metering chamber, when the pressurized dose is suddenly exposed to the atmosphere via the lower stem 32. Without the seal 48, a larger dose than intended could escape from the canister and be administered to the patient. Obviously this would defeat the purpose of a dose variable valve. Having similar function is an upper stem seal The upper stem seal 50 sits in the variable metering plug 44 and forms a seal between the upper portion 52 of the lower stem seal 32 and the variable metering plug.
The upper stem 54 rests in an orifice 56 in the variable metering plug 44. The upper stem includes a lower portion 58 formed to interconnect with the slot 42 formed in the lower stem 32. This interconnection provides a continuous stem having a substantially constant diameter. The upper stem has a lumen 60 extending there through, which as will be explained below provides fluid communication between the canister and the metering chamber. The upper stem further includes an upper orifice and lower orifices 62 and 64, respectively. These orifices 62 and 64 also connect the canister to the metering chamber. Further aspects of the upper stem include a disk 66 located between the upper and lower orifices 62,64. Protruding from this disk are arms 68. As shown in
A spring 72 is placed over the shaft 70 and rests on the disk 66. This spring provides the restorative bias that after actuation of the valve restores the valve to the at-rest position, as will be discussed in detail below.
A valve body 74 having an orifice 76, feet 78, and slots 80 is the final component of the dose variable valve. The valve body 74 is placed over the spring 72 that has been placed over the shaft 70. The valve body is lowered onto the variable metering plug 44, and the feet 78 engage holes 82 formed in the top surface of the variable metering plug 44. As shown in
When the valve body 74 is placed in position on the variable metering plug 44, the shaft 70 of the upper stem 54 projects out the orifice 76. The interaction of the orifice 76 and the shaft 70 provides a vertical alignment mechanism for the valve 10. Also when placed in this position the spring 72 is slightly pre-tensioned, forcing the disk 66 firmly against the top surface of the variable metering plug 44. The arms 68 which extend from the disk 66 extend through the slots 80.
When assembled, the forgoing components take the shape of the dose variable valve as shown in
As assembled, the lower stem 32 translates through the ferrule 12 and into the metering chamber housing 18 to engage the lower portion 58 of the upper stem 54. The metering chamber housing 18 and the variable metering plug 44 are threaded together. The metering chamber 100 is defined by the orientation of these two components, the further into the metering chamber housing 18 the variable metering plug 44 is threaded the smaller the metering chamber 100. Comparing
Because in practice the metering chamber housing 18 is fixed firmly against the ferrule 12 it does not move when the lower stem 32 is rotated. Rotation of the lower stem 32 acts on the upper stem 54 because the two are joined by the lower portion 58 of the upper stern 54 and the slot 42 of the lower stem. The rotational force applied to the lower stem 32 is translated through the upper stem 54 to the valve body 74 by the arms 68 that engage the slots 80 formed in the sides of the valve body 74. This rotational force applied to the valve body 74 is similarly translated to the variable metering plug 44 via the feet 78 which engage the holes 82. As a result, rotation of the lower stem 32 causes a similar rotation of the variable metering plug 44. The variable metering plug 44 having threads 46 which mate with the threads 26 of the metering chamber housing 18 can rotate along these threads. Thus, by rotating the lower stern 32, the size of the metering chamber 100 can be changed.
In the position shown in
Rotating the lower stem 32 as shown in
The dose variable valve 10, as shown above, allows the patient to set the precise amount of drug prescribed or deemed necessary at any particular time. The dose can be administered in a single inhalation, such that in certain instances multiple inhalations are generally not necessary. For example, the dose variable valve 10 may provide variable dosages from about 25 to 300 μl. In one preferred embodiment, the dosage from 25 to 300 μl can be accomplished in 12 equal 25 μl steps allowing for very precise and repeatable titration of dosage for the patient.
A variable dose inhaler 200 incorporating the dose variable valve 10, according to another aspect of the instant invention is depicted in
The inhaler 200 includes a units remaining indicator 206. As can be readily understood by those of skill in the art, in a device that has variable dosing characteristics, the accounting for the volume of medicament already administered and the amount of medication remaining in the device are important so that the patient is never in a situation where there are no doses remaining when they are in need of the medication. In practice, doses of medication are not counted as in the traditional dose counters but rather IU's or inhalation units are counted. As a result when a patient determines that they require a dose of 70 inhalation units as shown in
The following description is of a breath-actuated inhaler incorporating the dose variable valve and canister described above.
The inhaler 200 shown in
The cap 214 contains a spring 226 that rests in a spring holder 228 the spring holder 228 is keyed or affixed to the canister 110. The cap 214 also contains a cocking switch 230 which provides an electrical signal to the microprocessor when it senses that the inhaler has moved from the at-rest position shown in
The cap 214 includes a dial 202. The dial 202 is preferably mechanically connected to the canister 110. By this mechanical connection, rotation of the dial 202 rotates the canister 110. The lower stem 32 of the dose variable valve 10 is keyed to the base 216 of the inhaler 200 via, for example, the inhaler nozzle, to prevent its movement. As a result of the lower stem 32 being prevented from moving, rotation of the dial 202 forces the canister 110 to rotate in relation to the lower stem 32. As discussed above, rotation of the lower stem 32 in relation to the canister 110 changes the relationship between the variable metering plug 44 and the metering chamber housing 18 in the dose variable valve 10. As a result the user is able to adjust the size of a dose of medicament the inhaler 200 is to administer.
The inhaler includes a release mechanism which includes a rocker 232, a cam 234, a follower, 236, and a diaphragm 238. In
As mentioned above,
As shown in
In
Upon release of the follower 236 from the cam 234, the rocker 232 is free to pivot. With respect to
The expansion of the spring 226 is enabled by the release of the rocker 232. The spring 226 acts on the canister 110 on one side and against the spring holder 228 on the other side. The top portion of the spring holder 228 is held in pace by the rod 248 which is connected to the cover 210. The head 250 of the rod 248 prevents the expansion of the spring holder, 228 in the direction of the cap 214. The spring holder 228 does expand in the direction of the canister 110 as shown in
The movement of the canister 110 also causes an actuator sensor switch 252 to close, as can be seen by comparison of
The computer 224 will now be discussed with respect to
Another input received by the microprocessor is the cocking switch input 230A which is received once the inhaler has been cocked as shown in
The actuation sensor switch 252 or inhalation switch sends a signal 252A when it is depressed. This typically coincides with a user inhaling on the mouthpiece 208. This inhalation, as discussed above, triggers the inhaler to dispense the drug. Triggering causes the canister 210 to move in the direction of the base 216 and close the normally open actuation sensor switch 252. The closure of this switch sends a signal to the microprocessor 304 to start a clock signal that controls the illumination of the LED 204. The LED will be illuminated for as long as the microprocessor 304 has determined necessary for the desired dose. As described above, the microprocessor 304 performs a calculation based on the dose selector signal 306A. Once the actuation sensor switch 252 is switched on, the LED will be illuminated signaling to the user to continue inhalation. Upon expiry or the running of the clock to zero, the microprocessor 304 opens the circuit to the LED 204 extinguishing the light and signaling the user that they can stop inhaling.
Another feature of the actuation sensor switch 252 is that upon depressing the switch, the microprocessor 304 is signaled that a dose is being expelled from the canister 110. The amount of that dose is signaled by the dose selector 306. The microprocessor 304 uses the dose signal 306A in combination with the closing of the actuation sensor switch 252 to perform a calculation and deduct the amount of the dose from the IU's remaining LCD display 206. This may be done upon triggering of the sensor switch 252, or at a later time, for example, when the inhaler 200 is returned to its at-rest position shown in
The microprocessor 304 also receives an input from a temperature sensor 308 which provides a temperature signal 308A. As will be appreciated by those of skill in the art, the dispensation of a pressurized medicament as used in an inhaler will be affected by the temperature of the inhaler, which is generally near the ambient temperature. The higher the temperature, the higher the pressure that will be developed by the expansion of the propellant inside the canister 110.
By use of the forgoing microprocessor 304 as described with respect to
The microprocessor enables the user to set their desired dose and then have the inhaler indicated after each administration the number of IU's remaining so that the patient can manage their medication usage and guarantee that they are receiving the proper amount of medication dependent upon their needs.
Another aspect of the instant application is shown in
As shown in
The dial 202 and the cap 214 includes markings. The cap 214 has a reference marking and the dial 202 includes dose selection markings. By aligning the desired dose selection marking with the reference marking the user can dial in a dose to be administered by the inhaler 400.
The dial 202 is mechanically connected to canister 110. As a result, a rotation of the dial 202 results in a rotation of the canister 110 in relation to the stem 32 which is essentially held in position by the key securing means. Thus rotation of the canister 110 about the stem 32 results in a change of the relationship of the metering chamber housing 18 and the variable metering plug 44 to change the volume of the metering chamber 100, which are shown in detail in
Once a dose is selected, the user can then depress the cap 214 in the direction of the base 216 to effectuate the release of the dose of medicament or drug stored in the metering chamber 100, through the stem 32 and out the mouthpiece.
One aspect of the inhaler 400 shown in
According to one aspect of the invention, the lock could be part of the dial 202, and be re-settable. A key or unlocking mechanism may be provided to pharmacists to enable them to reset the inhaler 400 if for example, a subsequent prescription requires a larger dose be administered. In this manner, the patient does not have to purchase a new inhaler when receiving a new prescription. Alternatively, the lock could be part of the dose variable valve 10 and be a one time settable lock. Again this insures that the patient receives only the prescribed dose. Further, like the aspect above, the inhaler need not be replaced when transitioning to a new prescription, only the canister 110, which the pharmacists can set for the new prescription.
One benefit of such a device is that manufacturers need not prepare multiple different dosage canisters to be incorporated into an inhaler, rather, using a single inhaler a wide range of dosing parameters can be met.
Yet a further aspect of the present invention can be seen in
Nasal delivery as described herein has been found effective for a variety of drug treatments and through the use of the Valsalva Maneuver, whereby the pulmonary tract of the user is essentially shut off from the nasal passages by the exhalation of the user. This prevents the particles being delivered to the user from simply avoiding the nasal region and ending up in the lungs. This can be an important aspect of treatment as it is well known that the nasal epithelia are effective organs for absorption of drugs into the body. Because of absorption via the nasal epithelia bypasses the blood brain barrier, it is one of the most effective methods of transmitting systemic pharmaceutical products, for example insulin. Accordingly, the aspect of the instant invention shown in
One significant benefit of the devices described by the instant invention is the ability to alter dose size. This is important not just for administration of the proper amount of size but also to administer this dose in a single administration. For example, in the case of chronic obstructive pulmonary disease (COPD) and asthma, traditional dosing mechanisms are not always effective and may require the use of two or more inhalers providing different sized doses, or alternatively multiple doses from a single inhaler. This multiple dosing can lead to exhaustion on the part of the patient, who already has a diminished lung capacity and strength.
What is more, these multiple dosings may require multiple steps including shaking the inhaler between each administration as well as device preparatory steps or waiting between administrations. As a result, patients sometimes forget how many doses they have administered and often administer incomplete doses. This is quite understandable as these patients are often in the midst of an attack where breathing has become very difficult and their only goal is immediate relief.
The inhaler 200, for example, as shown in
Though some aspects of the instant invention are directed to providing consistent and repeatable doses to the pulmonary and/or nasal mucosa for delivery of insulin, the invention is not so limited and can be used for the treatment of any illness requiring either systemic or topical dosing. In addition to insulin and other medicaments for the treatment of diabetes, a variety of different types of formulations with bronchodilators can also be used in connection with the inhalers of the present invention.
Bronchodilators are intended to improve bronchial airflow and treatment of bronchial asthma is the most common application of these drugs. In addition to asthma bronchodilators help expand the airways and improve the breathing capacity of patients with emphysema, pneumonia and bronchitis. Salbutamol is a type of bronchodilator that can be used to aid in the treatment of chronic COPD and asthma that is characterized by the obstruction of airflow out of the lungs. Salbutamol being a short-acting β2-adrenergic receptor agonist binds to β2-adrenergic receptors leading to their activation thus relaxing the bronchial smooth muscles and widening the airways. Formoterol, a newer β2-adrenergic receptor agonist, aids in the same bronchodilation as salbutamol, but is long-acting. Duration of the effect of formoterol lasts about 12 hours, in comparison with 4-6 hours with salbutamol and it also has a faster onset than the latter.
Corticosteroids, which are the steroid hormones produced by the adrenal cortex, can also be put into formulations to be used in conjunction with the invention. Budesonide and fluticasone, which are types corticosteroids that have anti-inflammatory properties and are widely used against many inflammatory conditions, particularly for the treatment of asthma, non-infectious rhinitis. Formulations with a combination consisting of a corticosteroid (budesonide) and a bronchodilator (formoterol), which have been shown to have high efficacy, can also be used.
It is preferred that active ingredients in the formulations used in an inhaler as shown in
While certain formulations and diseases have been specifically discussed herein, the present invention is not so limited and may be used with any formulation deliverable with a metered dose inhaler.
Thus by the foregoing examples, the objects and advantages of the present invention are realized, and although preferred embodiments have been disclosed and described in detail herein, its scope and objects should not be limited thereby; rather its scope should be determined by that of the appended claims.
This application claims the benefit of U.S. Provisional Patent Application No. 60/842,552, filed Sep. 6, 2006, which is hereby incorporated by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
60842552 | Sep 2006 | US |